Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Rehabilitation Group Significantly Reduces Fatigue-Related Stress

August 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 8
Volume 10
Issue 8

TAMPA, Florida-A rehabilitation group program-Energy for Living With Cancer-has the ability to reduce fatigue-related distress and improve quality of life, according to program developer Sandra Holley, PhD, ARNP, a nurse scientist at the James A. Haley Veterans Administration Medical Center, Tampa. Dr. Holley presented her results in a poster session at the Oncology Nursing Society’s 26th Annual Congress.

TAMPA, Florida—A rehabilitation group program—Energy for Living With Cancer—has the ability to reduce fatigue-related distress and improve quality of life, according to program developer Sandra Holley, PhD, ARNP, a nurse scientist at the James A. Haley Veterans Administration Medical Center, Tampa. Dr. Holley presented her results in a poster session at the Oncology Nursing Society’s 26th Annual Congress.

The Energy for Living With Cancer program is a structured rehabilitation intervention designed to educate patients about cancer-related fatigue and to provide support and sharing among participants. Patients meet for 90 minutes once a week for 8 weeks.

The education component covers topics such as risk factors for fatigue, how fatigue affects daily living, and fatigue management strategies. In the sharing and support component, patients relay their experiences, share coping techniques, and provide emotional support for one another.

To test the effectiveness of the program, Dr. Holley conducted a prospective pre/post-test study involving 20 program participants. The mean age of the participants was 63.6 (range, 38 to 86). Six different types of cancer were represented, and 15 of the patients were receiving cancer therapy at the time.

At the start of the program, study participants completed the Cancer-Related Fatigue Distress Scale, the Center for Epidemiological Studies—Depression form, and the Functional Living Index—Cancer scale. Upon study completion, participants re-took the tests and completed a program rating form.

Program rating results indicated a high degree of patient satisfaction with the program. On a scale of 0 to 10, the mean rating in the program evaluation was 9.8. Patients indicated that the educational topics were relevant and beneficial and that the 8-week fatigue-management intervention provided much-needed information and emotional support.

Moreover, post-program test results showed significant improvements in fatigue-related distress and quality of life. Fatigue distress scores decreased from a mean of 192.95 to 145.45, and quality-of-life scores increased from 98.65 to 145.45—nearly a 50% improvement. Depression scores decreased from 24.05 to 21.0, but this difference was not statistically significant.

Dr. Holley said that these preliminary findings indicate that the Energy for Living With Cancer program is appropriate and beneficial for cancer patients experiencing fatigue, even for those who are quite debilitated.

Articles in this issue

Amifostine Can Reduce Xerostomia, Loss of Taste, Fibrosis, and Pain
Three-Dimensional Conformal Radiation Therapy Reduces Rectal Damage in Prostate Cancer Treatment
Can Concurrent Amifostine and 5-FU Permit Delivery of Higher Boost Doses of Radiation?
Preventing Severe Esophagitis Critical in Chemoradiotherapy for Lung Cancer
Upcoming Trial to Test Ability of Amifostine to Reduce Radiation-Induced Hypothyroidism
Amifostine Offers Little Advantage in Small Trial of Twice-Daily Radiation Plus Chemotherapy
Subcutaneous Amifostine Provides Protection Against Radiation-Induced Acute Xerostomia
Study to Test Amifostine in Cervical Cancer Patients Treated With Combined-Modality Therapy
Radioprotectants May Extend Use of Combined Chemotherapy and Radiation
Amifostine Ameliorates Pneumonitis and Esophagitis During Radiochemotherapy
Potentially Useful Predictors of Risk for Developing Postradiation Pneumonitis
Amifostine Trial Represents First FDA Approval of Treatment Interacting With Radiation
Amifostine Reduces Side Effects During Treatment for Advanced Lung Cancer
Intrarectal Amifostine Prevents Late Rectal Complications of Radiotherapy for Prostate Cancer
Experts Consider Statistical Issues in Designing Studies of Toxicity Modifiers

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Related Content

Data from an ongoing phase 1a/1b trial evaluating ZL-1310 in ES-SCLC will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

ZL-1310 Receives FDA Fast Track Designation for Extensive-Stage SCLC

Roman Fabbricatore
May 20th 2025
Article


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


In the UK, the Medicines and Healthcare products Regulatory Agency approved the belantamab mafodotin combinations in April 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

Belantamab Mafodotin Earns Japanese Approval in R/R Multiple Myeloma

Russ Conroy
May 19th 2025
Article

Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.

Zanidatamab Displays Safety, Efficacy in HER2-Expressing Gastric Cancer

Roman Fabbricatore
May 19th 2025
Article

Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.


For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC

Roman Fabbricatore
May 19th 2025
Article

For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

Related Content

Data from an ongoing phase 1a/1b trial evaluating ZL-1310 in ES-SCLC will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

ZL-1310 Receives FDA Fast Track Designation for Extensive-Stage SCLC

Roman Fabbricatore
May 20th 2025
Article


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


In the UK, the Medicines and Healthcare products Regulatory Agency approved the belantamab mafodotin combinations in April 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

Belantamab Mafodotin Earns Japanese Approval in R/R Multiple Myeloma

Russ Conroy
May 19th 2025
Article

Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.

Zanidatamab Displays Safety, Efficacy in HER2-Expressing Gastric Cancer

Roman Fabbricatore
May 19th 2025
Article

Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.


For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC

Roman Fabbricatore
May 19th 2025
Article

For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.